Novartis Eyeing US Market for Prexige Launch with Companion Test
February 10, 2010
Novartis Eyeing US Market for Prexige Launch with Companion Test
A Novartis spokesperson told Pharmacogenomics Reporter last week that the company "plans to have discussions with the FDA about the specific requirements for the approval of lumiracoxib when used in conjunction with a biomarker program."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Novartis Evaluating Submission Strategy for Painkiller Prexige in Various Countries Except US
August 12, 2009 / Pharmacogenomics Reporter - Novartis Using PGx to Resuscitate Previously Failed Pain Drug Prexige with Companion Dx
August 5, 2009 / Pharmacogenomics Reporter - Clovis Pulls Plug on Personalized Cancer Drug after Trial Shows No Benefit for Drug or Marker
November 14, 2012 / Pharmacogenomics Reporter - During Investor Day, Roche Highlights Personalized Medicine as Key Area for Future Growth
September 12, 2012 / Pharmacogenomics Reporter - FDA Approves Pfizer's Chronic Philadelphia Chromosome-Positive CML Drug Bosulif
September 5, 2012 / Pharmacogenomics Reporter